GlassScriptPhysician profile
Jitesh Joshi
NPI 1679737969
$2,629.95
in general payments reported to CMS, 2019-2025
19 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2021: $78.37 · 2022: $277 · 2023: $120 · 2024: $72.97 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,675 · Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,675.00 |
| Food and Beverage | $287.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,722.52 | 2021-2025 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2019 | |
| Btg International INC. | $117.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $90.88 | 2019-2021 | |
| Glaxosmithkline, LLC. | $90.73 | 2022 | |
| Gilead Sciences, INC. | $83.70 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $67.98 | 2022 | |
| Genentech USA, INC. | $60.30 | 2019 | |
| Pfizer INC. | $44.35 | 2023 | |
| Merck Sharp & Dohme LLC | $40.69 | 2019-2025 | Keytruda |
| Array Biopharma INC | $25.69 | 2024 | Braftovi, Mektovi, Lorbrena |
| Abbvie INC. | $25.58 | 2025 | |
| Celgene Corporation | $24.32 | 2025 | Reblozyl |
| Eisai INC. | $22.39 | 2024 | |
| Jazz Pharmaceuticals INC. | $21.94 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $21.93 | 2023 | Injectafer |
| Taiho Oncology, INC. | $18.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2019 | |
| Fortovia Therapeutics, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jitesh Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.